FDA Halts Vascular Genetics VEGF-2 Gene Therapy Heart Disease Trial
This article was originally published in The Gray Sheet
Executive Summary
FDA has placed a gene therapy trial to promote angiogenesis in coronary heart disease patients on clinical hold. The study was being conducted by Vascular Genetics Inc., under the leadership of Jeff Isner, MD, chief of cardiovascular medicine at St. Elizabeth's Medical Center in Boston.